|
|
|
|
| As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing. Additional critical raw materials also have batch-to-batch variability, which means the entire production process is a constant balancing act of adjusting the manufacturing process to create standardized manufacturing. Join Cell & Gene Live for a discussion on practical ways to overcome the challenges associated with batch-to-batch variation. Registration is free thanks to the support of Entegris. |
|
|
Sf-RVN Platform | We provide a rhabdovirus-free cell line that improves the safety profile of your bioprocesses combined with a chemically defined medium specifically formulated to get excellent growth and productivity while adhering to evolving regulatory requirements. | Request Information | MilliporeSigma |
|
|
|
|
Clinical And Regulatory Strategy | Novotech is recognized as the Asia-Pacific full-service CRO and has been instrumental in the success of over 1,000 clinical trial projects in key areas such as immuno-oncology, infectious diseases, vaccines, and orphan and rare diseases. | Request Information | Novotech |
|
|
FectoVIR-AAV GMP | FectoVIR®-AAV GMP ticks all the boxes to make each AAV-based gene therapy a success. FectoVIR®-AAV GMP ensures highest AAV titers with reproducible quality while ensuring maximum process robustness and process safety. | Request Information | Polyplus |
|
|
|
